Study for anti-GBM disease patients
Part of Immune system & allergy, Kidney & urinary, Lungs & breathing, Women’s health & pregnancy clinical trials.
This study looks at people with anti-GBM disease, a rare kidney condition, to learn more about the disease and its treatment. If you were diagnosed between 2010 and 2027, or have stored blood or urine samples from your diagnosis, you might be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with anti-GBM disease (a rare kidney condition where your immune system attacks your kidneys).
- For one part of the study, your diagnosis must have happened between January 1, 2010, and December 31, 2027.
- For another part, you must have stored blood or urine samples from the time you were diagnosed.
- For that part, your doctor must also know whether you were alive six months after your diagnosis.
- If you were diagnosed between 2010 and 2027, your doctor must have records of your first treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people in Russia with C3 glomerulopathy or IC-MPGN to understand how these kidney diseases progress over time. It does not test a new treatment, but gathers information from medical records and check-ups to learn more about the conditions.
This study looks for certain gene changes (GBA/PSAP) in people with multiple myeloma or MGUS. It aims to understand if these genes are linked to the disease, which may help guide future treatments.
This study looks at immune “B cells” in people with membranous nephropathy (a kidney disease). It includes people who have received or are being considered for B-cell–depleting treatment, aiming to better understand what drives the disease and how it may respond.
This study builds a kidney tissue “library” to help researchers analyze kidney disease in newer ways. It may help by improving how glomerular (kidney filter) diseases are understood over time, using samples from people who already had a biopsy.
This trial tests if daratumumab can help people with a kidney condition called MGRS, where abnormal proteins damage the kidneys. The goal is to see if the drug can reduce protein in the urine and protect kidney function.
This trial tests a combination of two drugs (daratumumab and bortezomib, plus a steroid called dexamethasone) for people with rare kidney conditions caused by abnormal proteins. The treatment targets the abnormal plasma cells to help protect your kidneys and improve your health.
Hear when a new Anti-Glomerular Basement Membrane Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.